Why Going Electric with Your Valve Control Can Be a Smart, Economic Choice

It’s comfortable to stick with a known commodity, but that can lead to becoming stuck in the past. That’s becoming the case with many water districts that aren’t exploring their valve control options.

Systems engineers are likely familiar with a traditional PLC, but, while the base product may be competitive with an electronic valve control in price, the extra costs for other necessary components needed to complete an installation can drive that price up.

James Parsons, Application Engineer at Cla-Val, said districts will buy a traditional product, “then, they’re going to stick it into a large enclosure, and they’re going to have to set up some kind of communications network back to a SCADA system.”

“You can look at the VC-22D as a single unit that has a relatively small footprint that encompasses all of those. It doesn’t require an enclosure, it has its own enclosure, and it’s watertight,” he said.

It also has its own communication capability built in like MODBUS, so there’s no use for extra cards.

Of course, things still can go wrong, but Cla-Val has built its brand on support for years, utilizing the expertise of people like Roger Lah, Technical Product Specialist.

“That’s part of our jobs is to help customers – typically over the phone – to go through that process if they need some assistance after it’s installed to add in some alarms or other functions that haven’t been used yet but are easily field adjusted,” Lah said.

Those valve specialists can quickly ascertain if there’s an issue and how to fix it, while generalist system integrators may struggle to zoom in on a specific product.

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More